PMID- 12683352
OWN - NLM
STAT- MEDLINE
DCOM- 20030501
LR  - 20151119
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 23
IP  - 1A
DP  - 2003 Jan-Feb
TI  - Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.
PG  - 49-62
AB  - Lung cancer accounts for approximately 30% of all cancer mortalities in the 
      United States. Small cell lung cancer (SCLC), which is an aggressive malignancy 
      with frequent and early metastases, accounts for about 15% of all of the lung 
      cancer cases with a dismal 5-year survival rate of < 5% with current standard 
      therapies. Early detection of SCLC is challenging, in part due to the lack of 
      adequate serum tumor markers. The goal of this review is to summarize the current 
      knowledge of circulating tumor cells and serum biomarkers in small cell lung 
      cancer. The role of circulating tumor cells in prognostication is controversial, 
      but may be better defined with advancing technologies of detection of such cells 
      with higher precision, and improved clinico-pathological correlations. The 
      current knowledge on the known serum cytokines and tumor biomarkers of SCLC, such 
      as CEA, chromogranin-A and neuron-specific enolase will be presented. Serum 
      cytokines, such as vascular endothelial growth factor (VEGF), stem cell factor 
      (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) are also discussed. 
      New findings in the search for novel diagnostic and therapeutic molecular markers 
      using the emerging genomics and proteomics technologies are emphasized. It is our 
      hope that validation of these new research platforms and technologies will result 
      in improved early detection, prognostication and finally treatment of SCLC with 
      potential novel molecularly-targeted therapeutics.
FAU - Ma, Patrick C
AU  - Ma PC
AD  - Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham and Womens's 
      Hospital, Harvard Medical School, Tufts-New England Medical Center, Tufts 
      University School of Medicine, Boston, MA, USA.
FAU - Blaszkowsky, Lawrence
AU  - Blaszkowsky L
FAU - Bharti, Ajit
AU  - Bharti A
FAU - Ladanyi, Andras
AU  - Ladanyi A
FAU - Kraeft, Stine-Kathrein
AU  - Kraeft SK
FAU - Bruno, Adam
AU  - Bruno A
FAU - Skarin, Arthur T
AU  - Skarin AT
FAU - Chen, Lan Bo
AU  - Chen LB
FAU - Salgia, Ravi
AU  - Salgia R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Small Cell/*blood/pathology
MH  - Humans
MH  - Lung Neoplasms/*blood/pathology
MH  - Neoplastic Cells, Circulating/*pathology
RF  - 125
EDAT- 2003/04/10 05:00
MHDA- 2003/05/02 05:00
CRDT- 2003/04/10 05:00
PHST- 2003/04/10 05:00 [pubmed]
PHST- 2003/05/02 05:00 [medline]
PHST- 2003/04/10 05:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2003 Jan-Feb;23(1A):49-62.